OncoMatch/Clinical Trials/NCT07689058
CAR-T in Relapsed/Refractory Multiple Myeloma
Is NCT07689058 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies CAR-T for multiple myeloma refractory.
Treatment: CAR-T — The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body. Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: multiple myeloma therapy
Received at least 3 prior multiple myeloma treatment lines of therapy
Must have received: immunomodulatory drug and proteasome inhibitor
double refractory to an IMiD and PI (refractory multiple myeloma as defined by IMWG consensus criteria)
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T therapy directed at any target
Cannot have received: BCMA-targeted therapy
Any therapy that is targeted to BCMA
Lab requirements
Blood counts
anc/platelets thresholds (unless cytopenias attributable to mm)
Kidney function
criteria specified in section 10
Liver function
criteria specified in section 10
Cardiac function
lvef ≥45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07689058 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, BCMA-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages